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Summary:  
The clinical performance of the Diazyme SARS-CoV-2 assay was evaluated and deemed appropriate for 
patient testing using a cohort of 54 PCR positive patients and an additional 235 negative samples.  The 
kinetics of IgM and IgG seroconversion in 14 PCR confirmed SARS-CoV-2 patients were characterized by 
SARS-CoV-2 IgM/IgG serology. Serology testing should be considered a complimentary test to support 
PCR testing to aid in the detection of asymptomatic cases and is useful for documenting previous 
exposures to SARS-CoV-2.   
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Abstract 
Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus 
that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19). Polymerase chain 
reaction (PCR) based tests are optimal and recommended for the diagnosis of an acute SARS-CoV-2 
infection. Serology tests for viral antibodies provide an important tool to diagnose previous exposure to 
the virus. Here we evaluate the analytical performance parameters of the Diazyme SARS-CoV-2 IgM/IgG 
serology assays and describe the kinetics of IgM and IgG seroconversion observed in patients with PCR 
confirmed COVID-19 who were admitted to our hospital.  
Methods. We validated the performance of the Diazyme assay in 235 subjects to determine specificity. 
Subsequently, we evaluated the SARS-CoV-2 IgM and IgG seroconversion of 54 PCR confirmed COVID-19 
patients and determined sensitivity of the assay at three different timeframes.  
Result. Sensitivity and specificity for detecting seropositivity at ≥ 15 days following a positive SARS-CoV-
2 PCR result, was 100.0% and 98.7% when assaying for the panel of IgM and IgG. The median time to 
seropositivity observed for a reactive IgM and IgG result from the date of a positive PCR was 5 days (IQR: 
2.75-9 days) and 4 days (IQR: 2.75-6.75 days), respectively.  
Conclusions. Our data demonstrates that the Diazyme IgM/IgG assays are suited for the purpose of 
detecting SARS-CoV-2 IgG and IgM in patients with suspected SARS-CoV-2 infections. For the first time, 
we report longitudinal data showing the evolution of seroconversion for both IgG and IgM in a cohort of 
acutely ill patients in the United States. We also demonstrate a low false positive rate in patients who 
were presumed to be disease free.  
 
Key words: SARS-CoV-2; antibody; serology; diagnosis; COVID-19 
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Introduction 
Most known coronaviruses are common respiratory viruses causing cold-like symptoms (1). 
However, two other beta-coronaviruses, SARS and MERS, caused severe respiratory infections with 
increased fatality rates of 10% and 35%, respectively (2,3). In December 2019, an outbreak of a third 
novel beta-coronavirus, SARS-CoV-2, has led to a global pandemic of the acute respiratory disease, 
COVID-19 (4,5). Common symptoms of this infection include fever, cough, shortness of breath, and viral 
pneumonia (6,7). Severe cases develop acute respiratory distress syndrome (ARDS) and septic shock. An 
estimated 14% have severe symptoms, 5% develope critical conditions, with fatality rates estimated to 
be 3.4% as of March 3, 2020 (8,9). The mortality risk is increased with age (>65 years old) and in 
individuals with comorbidities (e.g. hypertension, diabetes) (10). 
 As of May 8
th
, 2020 over 4 million people were infected with 275,000 deaths worldwide (11). 
While several countries have taken an approach to massively screen the general population combined 
with contact tracing to effectively control COVID-19 (12–15), implementation of testing in the United 
States (US) has been slower and therefore prioritized for specific groups in the population(16). The 
current standard for the diagnosis of acute COVID-19 is real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) for oral or nasal specimens (17,18).  
Clinically validated serologic tests can be used to document previous exposure to the virus. 
Serologic assays are essential for epidemiological studies, development of vaccines, evaluation of 
passive antibody therapy, and risk assessment. Accurate serological tests will improve our 
understanding of viral spread in the community, particularly in the asymptomatic population, and help 
guide control measures. Recent reports have described the analytical characteristics of newly developed 
serology assays and the seroconversion of SARS-CoV-2 IgM and IgG (6,19–24). Most assays described are 
ELISAs measuring IgG and IgM targeting the surface spike protein (S-protein), the receptor binding 
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domain of the spike protein (RDB), and the internal viral nucleoprotein (N-protein). The time to 
seroconversion is dependent on the antibodies being measured and the sensitivity of the assay. The 
reported time to IgM positivity ranges from 5 to 10 days following disease onset, whereas IgG positivity 
occurs between 13-21 days (19–22,24). Importantly, combining serology testing with PCR results can 
enhance COVID-19 detection sensitivity and accuracy. A study from Guo and colleagues demonstrated 
that the positive detection rate of a single PCR test went from 51.9% to 98.6% when combined with an 
IgM ELISA assay (20). Further characterization of SARS-CoV-2 antibody response is necessary to support 
COVID-19 diagnosis, epidemiological studies, and vaccine evaluation.  
Here we investigate a patient cohort of 54 SARS-CoV-2 PCR confirmed patients along with 
235SARS-CoV-2 presumed negative subjects. SARS-CoV-2 IgM and IgG reactivity was quantified in 
samples from these subjects using the Diazyme SARS-CoV-2 IgM/IgG platform. This includes the 
longitudinal sampling of 14 hospitalized patients who were seronegative for SARS-CoV-2 IgM and IgG on 
admission. Clinical validation parameters of the assay were also evaluated with the goal of achieving a 
better understanding of the utility and analytical performance of this assay.  
Materials and Methods 
Study Design and Patient Cohort 
Excess serum and plasma samples from a total of 289 subjects were collected in BD Vacutainer 
collection tubes (K-EDTA, lithium-Heparin plasma separator tubes, and/or serum separator tubes) under 
UCSD IRB protocol 181656. This included serum or plasma samples from 54 patients which tested PCR 
positive for SARS-CoV-2, 21 patients which tested PCR positive on a respiratory panel nucleic acid 
(RPNA) test for other infections, 24 patients which tested positive for antinuclear antibodies (ANA) or 
anti-double stranded DNA (dsDNA), 10 HIV positive patients, 78 apparently healthy subjects (no 
respiratory symptoms per self-report), and 102 patient samples that had been stored frozen (-20
o
C) 
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since 2018. The SARS-CoV-2 positive patient cohort consists of 54 patients at University of California San 
Diego Health (UCSD). Three additional groups within the cohort were generated to calculate sensitivity 
and specificity for SARS-CoV-2 IgM and IgG at three time-frames relative to a confirmed positive SARS-
CoV-2 PCR result: a ≤ 7 day group (n = 271), a between 8 – 14 day group (n=258), and a ≥ 15 day group 
(n=253). These three groups contained all the presumed negative subjects and all the PCR positive 
patients who had a blood sample draws in the specified timeframe. 
Confirmation of SARS-CoV-2 Positive Patients  
All 54 SARS-CoV-2 patients were confirmed positive for COVID-19 by  nucleic acid amplification 
test that had been clinically validated in our laboratory and had an emergency use authorization (EUA) 
listing. For the purposes of sensitivity and specificity calculations, all 54 SARS-CoV-2 confirmed patients 
were treated as a true positive for IgM and IgG serology. All remaining samples were considered true 
negatives. 
Serology 
Serology was performed on the Diazyme DZ-Lite 3000 plus clinical analyzer platform, with the 
Diazyme DZ-LITE 2019-nCoV IgG (CLIA) Assay Kit (Cat # 130219015M) and the Diazyme DZ-LITE 2019-
nCoV-2 IgM (CLIA) Assay Kit (Cat # 130219016M), in accordance with the manufacturer’s product insert. 
Plasma (Li-Heparin or K-EDTA) and serum samples were analyzed in a manner consistent with the 
package insert. Briefly, the Diazyme DZ-LITE SARS-CoV-2 IgG/IgM CLIA kit uses magnetic microbeads and 
SARS-CoV-2 recombinant nucleocapsid (N) and spike (S) proteins to capture IgG and IgM (Personal 
Communication with Diazyme). Detection of formed immune-complexes are achieved with N-(4-Amino-
Butyl)-N-Ethyl-Isoluminol (ABEI). The light signal is measured by a photomultiplier and is reported as 
calculated luminescence units per mL (AU/mL); values ≥ 1.00 AU/mL are considered reactive, while 
values < 1.00 AU/mL are considered non-reactive. 
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GenMark ePlex Respiratory Pathogen Nucleic Acid Test 
To identify patient specimens containing other PCR confirmed microbes than SARS-Cov-2, the 
respiratory pathogen nucleic acid (RPNA) test was performed on the GenMark ePlex. This panel detects 
Adenovirus (A-F), Coronavirus (229E, HKU1, NL63, OC42), Human Metapneumovirus, Human 
Rhinovirus/Enterovirus, Influenza A, B and C, Influenza 2009 H1N1, Parainfluenza (1-4), Respiratory 
Syncytial Virus (A and B), Chlamydia pneumoniae and Mycoplasma pneumoniae.  
Validation of Li-Heparin Plasma Separator Tubes (PST) 
Paired potassium EDTA and lithium heparin PST tubes were compared to cross-validate PST as an 
alternative to manufacturer validated collection tubes. This was done for 12 SARS-CoV-2 PCR positive 
patients as well as 20 apparently healthy subjects. Samples were subjected to a single freeze thaw (-80 
°C) and analyzed in parallel on the Diazyme SARS-CoV-2 IgM/IgG serology assay. 
Precision & Stability 
Precision was calculated across 4 days by running 5 batches of 5 replicates of the quality controls 
(QCs) supplied with the DZ-LITE SARS-CoV-2 IgG/IgM CLIA kit and with patient pools (Hi, Low and 
Negative) (n=25). Reactive patient pools were made by pooling SARS-CoV-2 PCR positive patient samples 
to create two sample pools with two different concentrations of IgG and IgM against SARS-CoV-2 (Hi and 
Low). Non-reactive patient pools were created by combining patient serum samples that were collected 
in 2018.  
Dilutional linearity  
Dilutional linearity for IgG across the lower end of the analytically measurable range (AMR) was 
performed by mixing one high (26.9 AU/mL) and one low (0.117 AU/mL) sample in 20% increments prior 
to analysis. Linearity for IgG across the upper end of the AMR was evaluated by mixing pooled patient 
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samples from a high pool (114.1 AU/mL) and low pool (0.011 AU/mL) in 10% increments prior to 
analysis. Dilutional linearity for IgM across the lower end of the AMR was evaluated by mixing one high 
(4.517 AU/mL) and one low (0.507 AU/mL) sample in 20% increments prior to analysis. Dilutional 
linearity for IgM across the upper end of the AMR was performed by mixing pooled patient samples 
from a high pool (11.85 AU/mL) and low pool (0.327 AU/mL) in 10% increments prior to analysis. 
Statistical Analyses 
 Data was analyzed using R in Rstudio and linear regression analysis for all figures was performed 
in Excel. Precision (%CV) was calculated by analysis of variance (ANOVA) and total precision (%CV) was 
calculated by the sum of squares.   
Results 
Validation of plasma collected in Li-heparin plasma separator tubes 
The Diazyme SARS-CoV-2 IgM/IgG serology assays have been validated by the manufacturer to 
analyze plasma collected in EDTA anti-coagulant tubes or serum. We investigated the use of Li-heparin 
plasma separator tubes (PST) as an alternative collection tube to improve testing flexibility. Linear 
regression analysis comparing the observed and measured AU/mL values for IgM and IgG in K-EDTA and 
PST collected plasma demonstrated strong agreement for IgM (R
2
 = 0.9719) and IgG (R
2
 = 0.9862) 
(Supplemental Figure 1A and 1B). Bland-Altman plots describing the observed bias between the AU/mL 
values for IgM and IgG indicate agreement over a wide range of values (Supplementary Figure 1C and 
1D). AU/mL values for samples collected in K-EDTA tubes ranged from 0.6 – 8.4 AU/mL for IgM and 4.9 – 
108.5 AU/mL for IgG, with the average biases being 1.0% for IgM and 0.4% for IgG. 
Precision profile 
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The precision profiles (%CV) of the SARS-CoV-2 IgM and IgG serology assays can be found in Table 
1 for the positive and negative quality controls (QCs) as well as three patient pools that were non-
reactive, moderately reactive, and highly reactive for both IgM and IgG. Within run precision ranged 
from 1.4% - 5.0% for IgM and from 0.1% -14.6% for IgG. Between-run precision ranged from 4.1% - 7.3% 
for IgM and from 0.2% - 34.1% for IgG. Total precision ranged from 4.3% - 8.0% for IgM and from 0.2% - 
37.1% for IgG. The high variation observed for IgG was only seen in the negative patient pool where all 
measured AU/mL values were well below the cutoff (near zero). Outside of the negative patient pool, 
the highest within-run, between-run, and total precision observed for IgG was 7.6%, 11.56%, and 
13.25%.  
Sample stability 
QC and patient sample pools were found to be stable on the DZ-Lite 3000 Plus analyzer for 12 
hours at 25°C (Supplementary Table 1). The maximum bias observed, ignoring the non-reactive patient 
pool, was 8.33% for IgM and -8.02% for IgG.  
Dilutional linearity  
Dilutional linearity was determined and linear regression analysis was used to describe the 
relationship between observed and expected AU/mL values following sample dilution (Supplementary 
Figure 2). The IgM assay was linear from 0-12 Au/L (R
2
= 0.946, y=0.9296x + 0.5441) and IgG assay was 
linear from 0-27 AU/mL (R
2
= 0.996, y=1.0082x - 0.4738) (Supplementary Figure 2A and 2B). Significant 
saturation was observed at the upper end of the measured range for IgG. 
Cross-reactivity 
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The cross-reactivity of the SARS-CoV-2 IgM and IgG assays were evaluated against 55 patients, 
with other conditions or respiratory pathogens (Table 2). We observed no cross-reactivity for either IgM 
or IgG in these patient samples, including 8 samples positive for non-COVID-19 coronavirus. 
Sensitivity and Specificity 
To calculate sensitivity and specificity for IgM and IgG, patient groups that fell into three different 
time-frames, were generated (Table 3, Supplementary Table 2 and Supplementary Table 3). The ≤ 7 
day group included 36 PCR positive patients, the between 8 – 14 day group included 23 PCR positive 
patients, and the ≥ 15 day group included 18 PCR positive patients. As expected, sensitivity for the ≤ 7 
day group was poor for IgM (58.3%), IgG (69.4%) and the IgM/IgG panel (69.4%) (Table 4). In contrast, 
sensitivity observed in the between 8 – 14 day group was greatly improved for IgM, IgG, and the 
IgM/IgG panel; 94.4%, 94.4%, and 94.4%, respectively. The ≥ 15 day group saw reduced sensitivity of for 
IgM (89.5%), however improvements were observed for IgG and the IgM/IgG panel of 94.7% and 
100.0%, respectively.  Specificity of the assay was excellent for both IgM, IgG, and IgM/IgG panel; 99.6%, 
99.1%, and 98.7%, respectively. 
Positive and negative predictive values and the impact of prevalence  
Positive and negative predictive values (PPV and NPV) were calculated for the ≥ 15 day patient 
group as well at different levels of COVID-19 disease prevalence (Table 5). The prevalence for COVID-19 
in the ≥ 15 day patient group was 7.1%, and the observed PPV for IgM, IgG, and IgG/IgM panel was 
94.4%, 89.4%, and 85.6%, respectively. The observed NPV for IgM, IgG, and IgM/IgG panel was 99.6%, 
99.6%, and 100.0%. The impact of disease prevalence on the PPV and NPV of the SARS-CoV-2 IgM and 
IgG assays has been calculated for different levels of disease prevalence as well (Table 5). The 
prevalence of 4.3% (139/3272) represents the percentage of positive SARS-CoV-2 PCR tests performed 
on patients presenting with acute symptoms of COVID at the UCSD as of April 15, 2020.  
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Longitudinal patient sampling 
We evaluated the time to seroconversion of SARS-CoV-2 IgM and IgG in 14 PCR confirmed 
patients that were initially admitted to the hospital and presented as seronegative (Figure 1A and 1B). 
Observed median seroconversion to IgM and IgG was 5 days and 4 days following a positive PCR result, 
respectively. Interquartile range (IQR) for IgM and IgG was calculated as 2.75-9 days for IgM and 2.75 – 
6.75 days for IgG. All 14 patients seroconverted to IgM and IgG over the course of their hospital 
admission.  
Discussion 
We report a cohort of 289 subjects which includes 54 confirmed as PCR positive for SARS-CoV-2, 
21 which tested positive on a respiratory panel nucleic acid (RPNA) test for other infections, 24 which 
tested positive for ANA or dsDNA, 10 HIV positive patients, 78 apparently healthy subjects, and 102 
serum samples from 2018 that were considered SARS-CoV-2 naïve. Our study evaluated several 
analytical parameters of the Diazyme SARS-CoV-2 IgM and IgG serology assays (precision, dilutional 
linearity, and sample stability) and found them to be appropriate for clinical testing for both SARS-CoV-2 
IgM and IgG reactivity. The sensitivity of the combined IgM/IgG assays observed in the ≤ 7 day group 
was poor (69.4%), confirming that acutely sick patients presenting shortly after symptom onset should 
receive PCR testing. However, when testing samples that fell between 8 – 14 days after the date of a 
confirmed SARS-CoV-2 PCR result, the clinical sensitivity was 94.4% when using IgM/IgG panel. 
Sensitivity was 100.0% when testing samples that were ≥ 15 days after a confirmed SARS-CoV-2 PCR 
result using the combined IgM/IgG panel. Specificity was highest when using IgM alone to detect 
seropositivity (99.6%) but the specificity was also high when using the panel (98.7%). Interestingly, the 
sensitivity for IgM seropositivity was lower (89.5%) in the ≥ 15 day group compared to the between 8 – 
14 day group (94.4%), which probably reflects antibody class switching. The clinical utility of this test is 
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still being determined, but it appears to be useful to complement PCR-based methods where getting an 
adequate sample is difficult and to detect past or current SARS-CoV-2 infections.  
The importance of disease prevalence on predictive values is often overlooked. Table 5, shows 
that the PPV is high when the disease prevalence is high, but that the PPV drops as low as 17.3% at a 
disease prevalence of 0.3%. As of April 15
th
 2020, the estimated prevalence of SARS-CoV-2 in acutely ill 
patients that had been prescreened for COVID symptoms at UCSD Health was about 4.3%, which leads 
to a PPV of 77.7% and NPV of 99.8% when using the panel of IgM/IgG (Table 5). Thus, the PPV will be 
poor if this test is used in a broader swath of the general population without symptoms and a low 
prevalence for SARS-CoV-2. This is not a negative reflection on the assay, but a reality of any screening 
technique. 
A look at the precision profile indicates acceptable between-run, within-run, and total precision 
for all samples tested.   The negative patient pool had a total CV of 37.1%, but this is acceptable for a 
blank sample where the small variance is magnified and not clinically significant (Table 1). Sample 
stability was robust at 25 °C as maximum biases observed for reactive samples was less than 10% 
(Supplementary Table 1). Dilution studies revealed good linearity up to an AU/mL of 12 AU/mL for IgM 
and 27 AU/mL for IgG. Due to the wider dynamic range of the IgG assay, saturation was observed for 
samples with AU/mL values that ranged from 48.1 – 107.6, with clear saturation at values around 100 
AU/mL (Supplementary Figure 2). Cross-reactivity of the assay towards other conditions and respiratory 
pathogens was not observed for 55 individual patients. Importantly, 8 patients with non-COVID 
coronavirus did not cross react with either the IgM or IgG (Table 2). Cross-reactivity for IgM and IgG of 
24 patients which had positive ANA titers > 1:40 or anti-dsDNA (>100), was not observed (Table 2). We 
also tested 10 HIV positive patient samples and found no cross reactivity for IgM or IgG (Table 2). 
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The median time to seroconversion of the 14 longitudinally sampled patients was observed to be 
5 days for IgM and 4 days for IgG, with IQRs of 2.75 – 9 days and 2.75 – 6.75 days, respectively (Figure 
1). We also investigated how these findings would translate relative to the number of days post-
symptom onset (PSO). Relative to symptom onset, the median time to seropositivity for IgM and IgG was 
10.5 days PSO and 9.5 days PSO, respectively. Inter-quartile ranges of the median PSO seroconversion 
were 8.0 – 12.3 days for IgM and 7.0 – 12.0 days for IgG.  
The fact that we observe IgG becoming seropositive in these patients before IgM indicates that 
our cutoff for IgM seropositivity may be too stringent or that the assay lacks sensitivity, as IgM is known 
to become seropositive before IgG (20). This could also be due to the presence of high levels of viral 
antigen, that could compete with the labeled antigen used to detect the presence of IgM against SARS-
CoV-2. We evaluated a 0.7 AU/mL cutoff for IgM and recalculated the median time to seropositivity 
observed for IgM in the 14 longitudinally sampled patients. As expected, the observed median time to 
IgM seropositivity was shortened to 3.5 days relative to the positive PCR result (Supplementary Table 
4). However, utilizing the lower cutoff would have generated two additional false positives across the 
entire cohort and thus we followed the manufactures recommendation and used a 1.0 AU/mL as the 
cutoff for a reactive IgM result. 
One of the limitations of our study is that 50 out of 54 of our SARS-CoV-2 PCR confirmed patients 
were admitted to the hospital and are likely to be more acutely sick compared to the average person 
that contracts COVID-19. However, 56% (30/54) of the patients were not intubated at the time of 
writing, suggesting that most patients were not in critical condition. Another limitation of our study is 
that one of our non-admitted patients (#37) had a past-medical history of common variable 
immunodeficiency for IgG (Table 3). This medical condition could explain why this patient was classified 
as being falsely negative for IgG 22 days following a positive SARS-CoV-2 PCR result. If this patient was 
dropped from the cohort, the sensitivity if the IgG assay at >15 days would have been 100%. More 
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serologic data is needed on SARS-CoV-2 PCR positive patients with mild symptoms who recovered at 
home as compared with our acutely ill patients who were generally hospitalized.  
Some reports have suggested that SARS-CoV-2 IgM could be used as an acute phase marker for 
recent infection (20,25). There are several reports on various viruses, including SARS coronavirus, that 
suggest IgM antibodies against viral proteins can persists months and even years after an acute infection 
(26–34). Therefore, care must be used when interpreting seropositivity for IgM; if there is a question 
about acute exposure and infectivity, PCR testing should be performed.  
In conclusion, our data demonstrates that the Diazyme IgM/IgG assay is suited for the purpose of 
detecting SARS-CoV-2 IgM and IgG in patients with suspected SARS-CoV-2 infections. This is the first 
report of longitudinal data showing the evolution of seroconversion for both IgM and IgG in a cohort of 
patients in the United States. We also demonstrate a low false positive rate in patients who were 
presumed to be disease free. This validation study serves as a potential template for other studies 
evaluating the analytical and clinical performance of SARS-CoV-2 assays. 
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Precision of Concentration Values (AU/mL) 
Sample 
 (Mean AU/mL, SD)
 
IgM Between-run 
%CV
 
IgM Within-run 
%CV
 
IgM Total %CV
 
Positive QC
 (3.88, 0.17)
 
7.3
 
3.3
 
8.0
 
Negative QC
 (0.48, 0.08)
 
4.1
 
1.4
 
4.3
 
Patient Pool Hi
 (5.87, 0.25)
 
5.2
 
4.1
 
6.6
 
Patient Pool Low
 (1.71, 0.08)
 
3.5
 
4.7
 
5.9
 
Patient Pool Negative
 (0.55, 0.03)
 
3.9
 
5.0
 
6.3
 
Sample
 
IgG Between-run 
%CV
 
IgG Within-run 
%CV
 
IgG Total %CV
 
Positive QC
 (3.97, 0.21)
 
9.5
 
3.8
 
10.2
 
Negative QC
 (0.00, 0.004)
 
0.2
 
0.1
 
0.2
 
Patient Pool Hi
 (71.5, 5.4)
 
7.5
 
7.6
 
10.7
 
Patient Pool Low
 (33.4, 2.5)
 
11.6
 
6.5
 
13.3
 
Patient Pool Negative
 (0.07, 0.01)
 
34.1
 
14.6
 
37.1
 
 
Table 1. Precision profile of the Diazyme SARS-CoV-2 IgM/IgG serology assay. Between-run, 
within-run and total precision was calculated from a total of 25 replicates run across 4 days. 
Mean AU/mL and standard deviations (N=25)  are shown in parentheses. 
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Conditions
 
Number of Samples Tested
 
Number of Reactive (IgG or IgM)
 
Human Metapneumovirus
 
3
 
0
 
Influenza A H1-20009 PCR
 
1
 
0
 
Mycoplasma Pneumoniae
 
1
 
0
 
Non COVID-19 Coronavirus
 
8
 
0
 
Parainfluenza 4 PCR
 
1
 
0
 
Respiratory Syncytial Virus A
 
2
 
0
 
Respiratory Syncytial Virus B
 
1
 
0
 
Rhinovirus/Enterovirus
 
4
 
0
 
Anti-dsDNA (>100)
 
4
 
0
 
Antinuclear Antibodies
 
20
 
0
 
HIV+ 10 0 
 
Table 2. Cross-reactivity of the Diazyme SARS-CoV-2 IgM/IgG serology assay towards serum or plasma 
from 55 patients with other conditions. 
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Table 3. Clinical Information for COVID-19 Positive Patients at UC San Diego Health from March – April 2020. 
  
   
Patient Sex Age BMI Symptoms 
Day* of First 
Symptoms 
Day* 
Hospitalized 
Day* of 
Intubation 
Past Medical History 
1 M 36 38.1 fever; cough; SOB -5 -1 2 hepatomegaly 
2 M 42 31.1 fever; cough; SOB; chills; 
body aches; sore throat; 
nausea; diarrhea; weakness 
-9 1 NA None 
3 M 57 29.2 fever; cough; SOB; loss of 
taste; nausea; vomiting; 
fatigue; body aches 
-3 0 6 None 
4 M 33 24.4 fever; cough; SOB; chills; 
body aches 
-11 -4 -2 HIV+; hyperlipidemia 
5 M 47 23.7 cough; fever; body aches; 
weakness; SOB 
-6 0 NA hyperlipidemia; 
hypertension 
6** M 82 23.3 cough; loss of appetite; 
lethargic 
-2 0 4 dementia 
7 M 71 30.8 cough; fever; SOB -3 0 NA alcoholic liver cirrhosis; 
CKD; diabetes 
8** M 73 26.6 cough; fever; SOB -7 0 2 hypertension 
9 F 25 21.9 cough; SOB; weakness -2 -13 NA CKD; diabetes; 
hypothyroidism 
10 M 56 26.1 fever; cough; body aches; 
diarrhea; weakness; chills 
-5 0 NA None 
11 F 33 32.2 fever; cough; SOB -5 0 0 pregnant 
12 M 43 28.9 fever; cough; SOB; 
weakness 
-3 0 3 None 
13 M 53 27.8 fever; cough; SOB; body 
aches; chills; diarrhea 
-3 3 5 diabetes; HIV+; 
hyperlipidemia; 
hyertension 
14 M 50 23.2 fever; cough; chills; body 
aches 
-4 0 NA asthma; HIV+; 
hyperlipidemia; meth 
use 
15** F 77 20.5 fever; SOB; weakness; 
fatigue; lethargy 
-2 0 5 dementia 
16 F 64 31.4 fever; cough; SOB; body 
aches; diarrhea 
-4 0 NA diabetes 
17 M 83 25.9 weakness 0 2 NA asthma; cancer; 
diabetes 
18 F 65 30.6 fever; weakness; diarrhea; 
body aches 
-4 -1 2 diabetes; hypertension 
19 M 59 25.3 cough; fever; SOB; loss of 
appetite; lethargic; diarrhea 
-8 -1 9 congestive heart failure; 
hypertension; 
hypothyroidism 
20 M 61 36.7 cough; fever; SOB -7 0 1 None 
21 M 41 22.1 cough; fever; SOB; nausea; 
diarrhea 
-9 0 NA None 
22 M 34 26 cough; fever; SOB -1 9 NA asthma 
23 M 39 24.4 cough; fever; chills -7 NA NA None 
24** M 76 28.6 cough; SOB -9 -1 0 None 
25 F 25 34.2 cough; fever; chills -1 0 NA cancer; diabetes 
26 M 52 28.1 SOB; fever; body aches -6 NA NA cancer 
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Table 3. Clinical Information for COVID-19 Positive Patients at UC San Diego Health from March – April 2020. 
Patient Sex Age BMI Symptoms 
Day* of First 
Symptoms 
Day* 
Hospitalized 
Day* of 
Intubation 
Past Medical History 
27 M 81 20.9 fever; fainting -7 -3 NA cancer 
28 M 60 28.3 cough; SOB; body aches; 
diarrhea 
-7 4 NA hypertension 
29 M 57 36.4 SOB; cough; diarrhea -10 0 NA diabetes; HIV+ 
30 F 37 23.2 fever; cough -5 0 NA None 
31 M 83 25.4 weakness -3 0 NA dementia 
32 F 40 35.9 cough; fever; SOB; body 
aches 
-8 -2 -1 None 
33 F 20 30.8 weakness; chills; chest pain -2 -2 NA diabetes 
34 F 38 32.5 fever; diarrhea -5 0 NA ectopic pregnancy 
35 M 45 26.7 cough; fever; SOB; body 
aches 
-10 NA NA asthma; hyperlipidemia 
36 F 71 32.1 cough; fever; SOB; diarrhea -5 -1 NA diabetes; hypertension 
37 M 31 23.1 fever; cough; loss of taste -9 NA NA IgG deficient 
38** F 88 30.3 cough; fever; SOB; fatigue -1 0 2 hypertension 
39 F 53 40.0 cough; fever; SOB; fatigue; 
body aches 
-9 0 NA None 
40** M 67 25.0 cough; fever; SOB; 
dizziness; loss of taste and 
smell 
-7 0 0 hypotension; heart 
failure 
41 F 46 45.8 cough; fever; SOB; body 
aches; chills 
-10 2 NA diabetes; hypertension; 
asthma 
42 M 37 28.5 cough; fever; SOB; body 
aches; chills 
-2 14 NA HIV+; meth use 
43 M 67 27.4 cough; SOB -5 0 5 None 
44 M 50 24.6 cough; fever; SOB; chills -22 -15 -8 hypertension 
45 M 64 34.9 cough; SOB -9 0 1 COPD; hypertension 
46 F 69 33.8 cough; fever; SOB -3 8 NA hypertension 
47 M 41 35.5 cough; fever SOB; fatigue -18 0 5 asthma 
48 M 65 28.2 cough; fever; SOB -2 0 8 multiple myeloma 
49** F 80 30.0 cough; fever; SOB; nausea; 
vomiting; chills 
-1 0 17 diabetes; hypertension; 
anemia 
50 F 90 26.2 cough; fever; nausea -2 3 NA hypertension 
51 M 90 19.6 cough; diarrhea -2 2 NA hypertension; CKD; 
cancer 
52 M 48 30.0 cough; fever; SOB; fatigue; 
headache 
-5 0 2 None 
53 F 91 12.7 cough; fever -7 0 NA hypertension; stroke 
54** F 46 28.8 cough; fever; SOB 0 -1 0 hypertension; diabetes; 
rheumatoid arthritis 
Abbreviations: NA, not applicable; SOB, shortness of breath; HIV, human immunodeficiency virus; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease  
*All days are calculated relative to the date of the first PCR positive result. 
**Deceased at time of writing 
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Statistical 
Measure
 
≤ 7 Post Symptom Onset             
(n=271)
 
8 - 14 Post Symptom Onset           
(n=258)
 
≥ 15 Post Symptom Onset            
(n=253)
 
IgM
 
IgG
 
IgM/IgG
 
IgM
 
IgG
 
IgM/IgG
 
IgM
 
IgG
 
IgM/IgG
 
Sensitivity
 
58.3%
 
69.4%
 
69.4%
 
94.4%
 
94.4%
 
94.4%
 
89.5%
 
94.7%
 
100.0%
 
Specificity
 
99.6%
 
99.1%
 
98.7%
 
99.6%
 
99.1%
 
98.7%
 
99.6%
 
99.1%
 
98.7%
 
Table 4. Sensitivity and specificity of the Diazyme SARS-CoV-2 IgM/IgG serology assay at different time-points following 
a positive SARS-CoV-2 PCR result  
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Prevalence (%)
 
IgM
 
IgG
 
IgM + IgG
 
Sensitivity 
(%)
 
Specificity 
(%)
 
PPV (%)
 
NPV (%)
 
Sensitivity 
(%)
 
Specificity 
(%)
 
PPV (%)
 
NPV (%)
 
Sensitivity 
(%)
 
Specificity 
(%)
 
PPV (%)
 
NPV (%)
 
20.0
 
89.5
 
99.6
 
98.2
 
98.6
 
94.7
 
99.1
 
96.5
 
98.6
 
100.0
 
98.7
 
95.1
 
100.0
 
7.1
 
94.4
 
99.6
 
89.4
 
99.6
 
85.6
 
100.0
 
4.3*
 
90.8
 
99.7
 
83.2
 
99.7
 
77.7
 
100.0
 
2.2
 
82.9
 
99.9
 
70.7
 
99.9
 
63.1
 
100.0
 
1.1
 
70.5
 
99.9
 
54.5
 
99.9
 
45.8
 
100.0
 
0.5
 
54.3
 
100.0
 
37.3
 
100.0
 
29.6
 
100.0
 
0.3
 
37.2
 
100.0
 
22.9
 
100.0
 
17.3
 
100.0
 
  
Table 5: Positive and negative predictive values at various levels of disease prevalence. 
Sensitivity and specificity is shown for seropositivity for samples ≥15 days after a confirmatory PCR test. 
* Estimated prevalence of SARS-CoV-2 in the high risk testing population at UC San Diego Health on April 16
th
, 2020  
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 Figure 1: Longitudinal Sampling Illustrates Seroconversion in SARS-CoV-2 Infected Patients.  
A, B) Seroconversion to IgM and IgG was monitored in longitudinal samples for 14 patients. AU/mL values 
for IgG and IgM are plotted on the Y-axis on a semi-log scale and the number of days relative to a positive 
PCR test is shown on the X-axis. Values ≥ 1.00 AU/mL indicate reactivity, while values < 1.00 AU/mL 
indicate a non-reactive result. The median and interquartile ranges for the time to seropositivity, relative 
to a positive SARS-CoV-2 PCR result, is shown for IgG and IgM.  
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